Recent Advancements in AAV-Vectored Immunoprophylaxis in the Nonhuman Primate Model
-
Published:2023-08-08
Issue:8
Volume:11
Page:2223
-
ISSN:2227-9059
-
Container-title:Biomedicines
-
language:en
-
Short-container-title:Biomedicines
Author:
Campbell Elena S. B.1, Goens Melanie M.1ORCID, Cao Wenguang2, Thompson Brad3, Susta Leonardo1ORCID, Banadyga Logan2ORCID, Wootton Sarah K.1ORCID
Affiliation:
1. Department of Pathobiology, University of Guelph, Guelph, ON N1G 2W1, Canada 2. Public Health Agency of Canada, Winnipeg, MB R3E 3R2, Canada 3. Avamab Pharma Inc., Calgary, AB T2T 2P9, Canada
Abstract
Monoclonal antibodies (mAbs) are important treatment modalities for preventing and treating infectious diseases, especially for those lacking prophylactic vaccines or effective therapies. Recent advances in mAb gene cloning from naturally infected or immunized individuals has led to the development of highly potent human mAbs against a wide range of human and animal pathogens. While effective, the serum half-lives of mAbs are quite variable, with single administrations usually resulting in short-term protection, requiring repeated doses to maintain therapeutic concentrations for extended periods of time. Moreover, due to their limited time in circulation, mAb therapies are rarely given prophylactically; instead, they are generally administered therapeutically after the onset of symptoms, thus preventing mortality, but not morbidity. Adeno-associated virus (AAV) vectors have an established record of high-efficiency in vivo gene transfer in a variety of animal models and humans. When delivered to post-mitotic tissues such as skeletal muscle, brain, and heart, or to organs in which cells turn over slowly, such as the liver and lungs, AAV vector genomes assume the form of episomal concatemers that direct transgene expression, often for the lifetime of the cell. Based on these attributes, many research groups have explored AAV-vectored delivery of highly potent mAb genes as a strategy to enable long-term expression of therapeutic mAbs directly in vivo following intramuscular or intranasal administration. However, clinical trials in humans and studies in nonhuman primates (NHPs) indicate that while AAVs are a powerful and promising platform for vectored immunoprophylaxis (VIP), further optimization is needed to decrease anti-drug antibody (ADA) and anti-capsid antibody responses, ultimately leading to increased serum transgene expression levels and improved therapeutic efficacy. The following review will summarize the current landscape of AAV VIP in NHP models, with an emphasis on vector and transgene design as well as general delivery system optimization. In addition, major obstacles to AAV VIP, along with implications for clinical translation, will be discussed.
Funder
Canadian Institutes of Health Research Public Health Agency of Canada
Subject
General Biochemistry, Genetics and Molecular Biology,Medicine (miscellaneous)
Reference64 articles.
1. Successful Vaccines;Hangartner;Vaccination Strategies Against Highly Variable Pathogens,2018 2. Welles, H.C., Jennewein, M.F., Mason, R.D., Narpala, S., Wang, L., Cheng, C., Zhang, Y., Todd, J.-P., Lifson, J.D., and Balazs, A.B. (2018). Vectored Delivery of Anti-SIV Envelope Targeting MAb via AAV8 Protects Rhesus Macaques from Repeated Limiting Dose Intrarectal Swarm SIVsmE660 Challenge. PLoS Pathog., 14. 3. Marcotte, H., and Hammarström, L. (2015). Mucosal Immunology, Elsevier. 4. Antibody-Based Protection against HIV Infection by Vectored Immunoprophylaxis;Balazs;Nature,2012 5. Cleavage Efficient 2A Peptides for High Level Monoclonal Antibody Expression in CHO Cells;Chng;mAbs,2015
|
|